|Issuer:||SESEN BIO, INC. (SESN)|
|Original Submission Date:|
C/O SESEN BIO, INC.
245 FIRST STREET, SUITE 1800 CAMBRIDGE, MA 02142
|Title of Security||Transaction Date||2a. Deemed Execution Date||Transaction Code||Shares||Acquired or Disposed||Price per share||5. Amount of Securities Beneficially Owned Following Reported Transaction||6. Ownership Form Direct or Indirect||Nature of Indirect Ownership|
|Title of Derivative Security||Conversion or Exercise Price of Derivative Security||Transaction Date||Deemed Execution Date||Transaction Code||Number of Derivative Securities Acquired (A) or Disposed of (D)||Date Exercisable||Expiration Date||Title and Amount of Securities Underlying Derivative Security||Price of Derivative Security||Number of derivative Securities Beneficially Owned Following Reported Transaction(s)||Ownership Form: Direct (D) or Indirect (I)||Nature of Indirect Beneficial Ownership|
|STOCK OPTION||2.79||2021-05-03||deemed execution date||A||92,500 (a)||2031-05-03||common stock 92,500||$2.79||92,500||direct|
|f1||the option was granted on may 3, 2021 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested. in april 2021, sesen bio, inc.'s compensation committee, based on market analysis by radford, recommended to the sesen bio, inc. board of directors, and the board of directors approved, an increase in non-employee director equity compensation from the 50th percentile to the 75th percentile of the radford market analysis of public, pre-commercial biopharmaceutical companies with less than 200 employees and market values between $250 million and $1 billion. the option granted to purchase 92,500 shares of sesen bio, inc.'s common stock was equivalent to the 75th percentile of such radford market analysis.|